Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 1
2017 1
2019 1
2020 3
2021 4
2022 8
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
A Blood Test for the Diagnosis of Multiple Sclerosis.
Giuliano P, La Rosa G, Capozzi S, Cassano E, Damiano S, Habetswallner F, Iodice R, Marra M, Pavone LM, Quarantelli M, Vitelli G, Santillo M, Paternò R. Giuliano P, et al. Among authors: habetswallner f. Int J Mol Sci. 2024 Jan 30;25(3):1696. doi: 10.3390/ijms25031696. Int J Mol Sci. 2024. PMID: 38338973 Free PMC article.
Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.
De Lorenzo A, Liberatore G, Doneddu PE, Manganelli F, Cocito D, Briani C, Fazio R, Mazzeo A, Schenone A, Di Stefano V, Cosentino G, Marfia GA, Benedetti L, Carpo M, Filosto M, Antonini G, Clerici AM, Luigetti M, Matà S, Rosso T, Lucchetta M, Siciliano G, Lauria Pinter G, Cavaletti G, Inghilleri M, Cantisani T, Notturno F, Ricciardi D, Habetswallner F, Spina E, Peci E, Salvalaggio A, Falzone Y, Strano C, Gentile L, Vegezzi E, Mataluni G, Cotti Piccinelli S, Leonardi L, Romano A, Nobile-Orazio E; Italian CIDP Database Study Group. De Lorenzo A, et al. Among authors: habetswallner f. Eur J Neurol. 2024 Apr;31(4):e16190. doi: 10.1111/ene.16190. Epub 2024 Jan 2. Eur J Neurol. 2024. PMID: 38165011
Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy.
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Di Gennaro G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAFIRST (Brivaracetam Add‐On First Italian Network Study) Group Membership. Lattanzi S, et al. Epilepsia. 2023 Nov;64(11):2922-2933. doi: 10.1111/epi.17740. Epub 2023 Sep 9. Epilepsia. 2023. PMID: 38079181 Free article.
Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Saccà F, Sgarzi M, deRuyck F, Paci S, Phillips G, Crippa L, Veronesi C, Perrone V, Degli Esposti L; LHU study group. Antonini G, et al. Among authors: habetswallner f. Heliyon. 2023 May 20;9(6):e16367. doi: 10.1016/j.heliyon.2023.e16367. eCollection 2023 Jun. Heliyon. 2023. PMID: 37274644 Free PMC article.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy.
Vitale MG, Crispo A, Arundine D, Ronga R, Barbato C, Luongo A, Habetswallner F, De Martino BM, Maione A, Eisenwagen S, Vitale G, Riccardi F. Vitale MG, et al. Among authors: habetswallner f. Front Pharmacol. 2022 Nov 8;13:874028. doi: 10.3389/fphar.2022.874028. eCollection 2022. Front Pharmacol. 2022. PMID: 36425572 Free PMC article.
Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study.
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Di Gennaro G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) Group. Lattanzi S, et al. Neurol Ther. 2022 Dec;11(4):1789-1804. doi: 10.1007/s40120-022-00402-3. Epub 2022 Sep 16. Neurol Ther. 2022. PMID: 36109431 Free PMC article.
25 results